• Brentuximab vedotin with chemotherapy for patients with previously untreated Stage III/IV classical hodgkin lymphoma: 5-Year update of the ECHELON-1 study

      Ramchandren, R.; Dlugosz-Danecka, M.; Connors, J. M.; Radford, John A; Illes, A.; Picardi, M.; Lech-Maranda, E.; Feldman, T.; Smolewski, P.; Savage, K. J.; et al. (2021)
      Objective: Historically, nearly all relapses in classical Hodgkin lymphoma (cHL) occur within the fi rst 5 years of treatment (Radford et al., BMJ 1997;314:346). In ECHELON-1, brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine (A+AVD) signifi cantly improved modifi ed progression-free survival (PFS) versus doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) in patients with stage III/IV cHL (Connors et al., NEJM 2018;378:331). We report updated effi cacy and safety results; median follow-up was 60.9 months. Design: This phase 3, open-label study (NCT01712490) randomized patients with previously untreated stage III/IV cHL to receive 6 cycles of A+AVD or ABVD. Patients underwent an interim positron emission tomography scan after cycle 2 (PET2). An exploratory analysis of PFS per investigator was conducted. Results: There were 664 and 670 patients randomized to receive A+AVD and ABVD, respectively. 64%, 62%, and 58% of patients had stage IV disease, extranodal involvement at diagnosis, and B symptoms, respectively. Five-year PFS was 82.2% (95% confi dence interval [CI]: 79.0–85.0) with A+AVD and 75.3% (95% CI: 71.7–78.5) with ABVD. Overall, PFS favored A+AVD (hazard ratio [HR]: 0.681; 95% CI: 0.534–0.867; P=0.002). PFS benefi ts were observed regardless of PET2 status and International Prognostic Score. Estimated 5-year PFS with A+AVD versus ABVD was 84.9% versus 78.9% in PET2-negative patients (HR: 0.663; 95% CI: 0.502–0.876; P=0.004), and 60.6% versus 45.9% in PET2-positive patients (HR: 0.702; 95% CI: 0.393–1.255; P=0.229). Treatment-emergent peripheral neuropathy (PN) resolved or improved in 85% (n=375/443) and 86% (n=245/286) of the patients with PN on A+AVD and ABVD, respectively. Secondary malignancies occurred in 19 and 29 patients with A+AVD and ABVD, respectively. A total of 131 female patients or partners of male patients reported a pregnancy; both arms showed similar proportions of ongoing pregnancies or live births. Conclusions: At 5 years, A+AVD still demonstrates clinically meaningful improvement in PFS versus ABVD, independent of PET2 status, with a manageable safety profi le, including resolution or improvement of PN. The PFS benefi t observed with A+AVD at this important milestone suggests that A+AVD is an attractive treatment option for all patients with previously untreated stage III/IV cHL
    • Brentuximab vedotin with chemotherapy for stage 3/4 classical Hodgkin lymphoma: three-year update of the ECHELON-1 study

      Straus, DJ; Dlugosz-Danecka, M; Alekseev, S; Illes, A; Picardi, M; Lech-Maranda, E; Feldman, T; Savage, KJ; Smolewski, P; Bartlett, NL; et al. (2019)
    • Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial

      Straus, D. J.; Długosz-Danecka, M.; Connors, J. M.; Alekseev, S.; Illés, Á.; Picardi, M.; Lech-Maranda, E.; Feldman, T.; Smolewski, P.; Savage, K. J.; et al. (2021)
      Background: Despite advances in the treatment of Hodgkin lymphoma with the introduction of PET-adapted regimens, practical challenges prevent more widespread use of these approaches. The ECHELON-1 study assessed the safety and efficacy of front-line A+AVD (brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine) versus ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) in patients with stage III or IV classical Hodgkin lymphoma. The primary analysis showed improved modified progression-free survival with A+AVD. We present an updated analysis of ECHELON-1 at 5 years, an important landmark for this patient population. Methods: ECHELON-1 was an international, open-label, randomised, phase 3 trial done at 218 clinical sites, including hospitals, cancer centres, and community clinics, in 21 countries. Previously untreated patients (≥18 years with an Eastern Cooperative Oncology Group performance status of ≤2) with stage III or IV classical Hodgkin lymphoma were randomly assigned (1:1) to receive A+AVD (brentuximab vedotin, 1·2 mg/kg of bodyweight, doxorubicin 25 mg/m2 of body surface area, vinblastine 6 mg/m2, and dacarbazine 375 mg/m2) or ABVD (doxorubicin 25 mg/m2, bleomycin 10 U/m2, vinblastine 6 mg/m2, and dacarbazine 375 mg/m2) intravenously on days 1 and 15 of each 28-day cycle for up to six cycles. Stratification factors included region (Americas vs Europe vs Asia) and International Prognostic Score risk group (low, intermediate, or high risk). The primary endpoint was modified progression-free survival; this 5-year update includes analysis of progression-free survival as per investigator assessment in the intention-to-treat population, which was an exploratory endpoint, although the 5-year analysis was not prespecified in the protocol. This trial is registered with ClinicalTrials.gov (NCT01712490) and EudraCT (2011-005450-60), and is ongoing. Findings: Between Nov 19, 2012, and Jan 13, 2016, 1334 patients were randomly assigned to receive A+AVD (n=664) or ABVD (n=670). At a median follow-up of 60·9 months (IQR 52·2-67·3), 5-year progression-free survival was 82·2% (95% CI 79·0-85·0) with A+AVD and 75·3% (71·7-78·5) with ABVD (hazard ratio [HR] 0·68 [95% CI 0·53-0·87]; p=0·0017). Among PET-2-negative patients, 5-year progression-free survival was higher with A+AVD than with ABVD (84·9% [95% CI 81·7-87·6] vs 78·9% [75·2-82·1]; HR 0·66 [95% CI 0·50-0·88]; p=0·0035). 5-year progression-free survival for PET-2-positive patients was 60·6% (95% CI 45·0-73·1) with A+AVD versus 45·9% (32·7-58·2) with ABVD (HR 0·70 [95% CI 0·39-1·26]; p=0·23). Peripheral neuropathy continued to improve or resolve over time with both A+AVD (375 [85%] of 443 patients) and ABVD (245 [86%] of 286 patients); more patients had ongoing peripheral neuropathy in the A+AVD group (127 [19%] of 662) than in the ABVD group (59 [9%] of 659). Fewer secondary malignancies were reported with A+AVD (19 [3%] of 662) than with ABVD (29 [4%] of 659). More livebirths were reported in the A+AVD group (n=75) than in the ABVD group (n=50). Interpretation: With 5 years of follow-up, A+AVD showed robust and durable improvement in progression-free survival versus ABVD, regardless of PET-2 status, and a consistent safety profile. On the basis of these findings, A+AVD should be preferred over ABVD for patients with previously untreated stage III or IV classical Hodgkin lymphoma.
    • Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin's lymphoma.

      Connors, J; Jurczak, W; Straus, D; Ansell, S; Kim, W; Gallamini, A; Younes, A; Alekseev, S; Illés, Á; Picardi, M; et al. (2017-12-10)
      Background Brentuximab vedotin is an anti-CD30 antibody-drug conjugate that has been approved for relapsed and refractory Hodgkin's lymphoma. Methods We conducted an open-label, multicenter, randomized phase 3 trial involving patients with previously untreated stage III or IV classic Hodgkin's lymphoma, in which 664 were assigned to receive brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine (A+AVD) and 670 were assigned to receive doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD). The primary end point was modified progression-free survival (the time to progression, death, or noncomplete response and use of subsequent anticancer therapy) as adjudicated by an independent review committee. The key secondary end point was overall survival. Results At a median follow-up of 24.9 months, 2-year modified progression-free survival rates in the A+AVD and ABVD groups were 82.1% (95% confidence interval [CI], 78.7 to 85.0) and 77.2% (95% CI, 73.7 to 80.4), respectively, a difference of 4.9 percentage points (hazard ratio for an event of progression, death, or modified progression, 0.77; 95% CI, 0.60 to 0.98; P=0.03). There were 28 deaths with A+AVD and 39 with ABVD (hazard ratio for interim overall survival, 0.72 [95% CI, 0.44 to 1.17]; P=0.19). All secondary efficacy end points trended in favor of A+AVD. Neutropenia occurred in 58% of the patients receiving A+AVD and in 45% of those receiving ABVD; in the A+AVD group, the rate of febrile neutropenia was lower among the 83 patients who received primary prophylaxis with granulocyte colony-stimulating factor than among those who did not (11% vs. 21%). Peripheral neuropathy occurred in 67% of patients in the A+AVD group and in 43% of patients in the ABVD group; 67% of patients in the A+AVD group who had peripheral neuropathy had resolution or improvement at the last follow-up visit. Pulmonary toxicity of grade 3 or higher was reported in less than 1% of patients receiving A+AVD and in 3% of those receiving ABVD. Among the deaths that occurred during treatment, 7 of 9 in the A+AVD group were associated with neutropenia and 11 of 13 in the ABVD group were associated with pulmonary-related toxicity. Conclusions A+AVD had superior efficacy to ABVD in the treatment of patients with advanced-stage Hodgkin's lymphoma, with a 4.9 percentage-point lower combined risk of progression, death, or noncomplete response and of subsequent anticancer therapy at 2 years. (Funded by Millennium Pharmaceuticals and Seattle Genetics; ECHELON-1 ClinicalTrials.gov number, NCT01712490 ; EudraCT number, 2011-005450-60 .).
    • Brentuximab vedotin with chemotherapy for Stage III/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study

      Straus, DJ; Dlugosz-Danecka, M; Alekseev, S; Illes, A; Picardi, M; Lech-Maranda, E; Feldman, T; Smolewski, P; Savage, KJ; Bartlett, NL; et al. (2020)
      The phase 3 ECHELON-1 study demonstrated that brentuximab vedotin (A) with AVD (A+AVD) exhibited superior modified PFS versus ABVD for the frontline treatment of patients with stage III/IV classical Hodgkin lymphoma (cHL) (NCT01712490; 2011-005450-60). Maturing data from positron emission tomography (PET)-adapted trials highlight potential limitations of PET-adapted approaches, including toxicities with dose intensification and higher-than-expected relapse rates in PET2(-) patients. We present here an update of the ECHELON-1 study, including an exploratory analysis of 3-year PFS per investigator. 1334 patients with stage III or IV cHL were randomized 1:1 to receive six cycles of A+AVD (n = 664) or ABVD (n = 670). Interim PET scan after cycle 2 (PET2) was required. At a median follow-up of 37 months, 3-year PFS rates were 83.1% with A+AVD and 76.0% with ABVD; 3-year PFS rates in PET2(-) patients aged <60 years were 87.2% versus 81.0%, respectively. A beneficial trend in PET2(+) patients aged <60 years on A+AVD was also observed, with a 3-year PFS rate of 69.2% versus 54.7% with ABVD. The benefit of A+AVD in the intent-to-treat population appeared independent of disease stage and prognostic risk factors. Upon continued follow-up, 78% of patients with peripheral neuropathy (PN) on A+AVD had either complete resolution or improvement compared with 83% on ABVD. These data highlight that A+AVD provides a durable efficacy benefit compared with ABVD for frontline stage III/IV cHL which is consistent across key subgroups regardless of patient status at PET2, without need for treatment intensification or exposure to bleomycin.
    • Bridging the gap in cancer care for teenagers and young adults

      Smith, S; Wright, David; Pennington, L; Jones, C; Haniak, C; Waterhouse, K; Kelly, J; Ashley, N; Coad, J; Teenage Cancer Trust Services London (2015)
    • Bridging the gap: metabolic and endocrine care of patients during transition.

      Hokken-Koelega, A; van der Lely, A; Hauffa, B; Häusler, G; Johannsson, G; Maghnie, M; Argente, J; DeSchepper, J; Gleeson, H; Gregory, J; et al. (2016-11)
      Seamless transition of endocrine patients from the paediatric to adult setting is still suboptimal, especially in patients with complex disorders, i.e., small for gestational age, Turner or Prader-Willi syndromes; Childhood Cancer Survivors, and those with childhood-onset growth hormone deficiency.
    • Brief report on the clinical characteristics of patients whose samples generate small cell lung cancer circulating tumour cell derived explants

      Vickers, Alexander J; Frese, Kristopher K; Galvin, Melanie; Carter, Mathew; Franklin, Lynsey; Morris, Karen; Pierce, Jackie; Descamps, Tine; Blackhall, Fiona H; Dive, Caroline; et al. (2020)
      Introduction: Small cell lung cancer (SCLC) has a dismal prognosis. Circulating tumour cells (CTCs) can be used to generate CTC derived explants (CDX) for the study of SCLC biology and the development of novel therapeutics. We investigated whether there are demographic or clinical predictors of the success of CDX generation, and whether CDX models are representative of the SCLC patient population. Methods: This was a single centre, retrospective analysis of SCLC patients who had participated in the CHEMORES Study. Paired blood samples were donated for CTC enumeration and CDX generation attempt at pre-treatment baseline, disease progression and intervening timepoints. Clinical and demographic data was collected from electronic records, and analysed for differences between patients whose samples did and did not generate a CDX. Results: 231 paired blood samples were taken from 147 patients. 45 CDX were generated from 34 patients. CTC number was significantly higher in blood samples which successfully generated a CDX than those which didn't, at both baseline (p=<0.0001) and progression (p = 0.0001). The group with successful blood samples had a poorer performance status (p = 0.0067), and a higher proportion of patients with chemorefractory disease (p = 0.0077). Both progression free survival (PFS) (p = 0.0132) and overall survival (p=< 0.0001) were significantly shorter for patients with successful samples. Conclusions: Patients whose samples generate CDX models may have a higher disease burden and more aggressive disease. Thus, insights gained by study of SCLC CDX may have a significant impact, particularly in the SCLC subpopulation with the greatest clinical need.
    • Brief report: Four-year survival with durvalumab after chemoradiotherapy in Stage III NSCLC - an update from the PACIFIC trial

      Faivre-Finn, Corinne; Vicente, D.; Kurata, T.; Planchard, D.; Paz-Ares, L.; Vansteenkiste, J. F.; Spigel, D. R.; Garassino, M. C.; Reck, M.; Senan, S.; et al. (2021)
      Introduction: In the Phase 3, placebo-controlled PACIFIC trial of patients with unresectable, stage III NSCLC without disease progression after concurrent chemoradiotherapy, consolidative durvalumab was associated with significant improvements in the primary end points of overall survival (OS) (hazard ratio [HR] = 0.68; 95% confidence interval [CI]: 0.53-0.87; p = 0.00251; data cutoff, March 22, 2018) and progression-free survival (PFS) (blinded independent central review; Response Evaluation Criteria in Solid Tumors version 1.1) (HR = 0.52; 95% CI: 0.42-65; p < 0.0001; February 13, 2017) with manageable safety. Here, we report updated analyses of OS and PFS, approximately 4 years after the last patient was randomized. Methods: Patients with WHO performance status of 0 or 1 (and any tumor programmed death-ligand 1 status) were randomized (2:1) to intravenous durvalumab (10 mg/kg) or placebo, administered every 2 weeks (≤12 months), stratified by age, sex, and smoking history. OS and PFS were analyzed using a stratified log-rank test in the intent-to-treat population. Medians and 4-year OS and PFS rates were estimated by the Kaplan-Meier method. Results: Overall, 709 of 713 randomized patients received durvalumab (n/N=473/476) or placebo (n/N=236/237). As of March 20, 2020 (median follow-up = 34.2 months; range: 0.2-64.9), updated OS (HR = 0.71; 95% CI: 0.57-0.88) and PFS (HR = 0.55; 95% CI: 0.44-0.67) remained consistent with the primary analyses. The median OS for durvalumab was reached (47.5 mo; placebo, 29.1 months). Estimated 4-year OS rates were 49.6% versus 36.3% for durvalumab versus placebo, and 4-year PFS rates were 35.3% versus 19.5% respectively. Conclusion: These updated exploratory analyses demonstrate durable PFS and sustained OS benefit with durvalumab after chemoradiotherapy. An estimated 49.6% of patients randomized to durvalumab remain alive at 4 years (placebo, 36.3%), and 35.3% remain alive and progression-free (placebo, 19.5%).
    • Brief report: three-year overall survival with durvalumab after chemoradiotherapy in stage III NSCLC - Update from PACIFIC

      Gray, JE; Villegas, A; Daniel, D; Vicente, D; Murakami, S; Hui, R; Kurata, T; Chiappori, A; Lee, KH; Cho, BC; et al. (2019)
    • A brief review of the breast cancer prevention trials.

      Cuzick, Jack; Howell, Anthony; Imperial Cancer Research Fund Statistics and Epidemiology Unit, 61 Lincoln's Inn Fields, WC2A 3PX, London, UK. j.cuzick@icrf.icnet.uk (2000-09)
    • Brief review of the fibronexus and its significance for myofibroblastic differentiation and tumor diagnosis.

      Eyden, Brian P; Department of Histopathology, Christie Hospital National Health Service Trust Manchester, UK. (1993)
      This brief review details the structure, nature, and distribution of the fibronexus, and discusses its significance for myofibroblastic differentiation and tumor diagnosis. The fibronexus is a cell surface specialization consisting of intracellular actin filaments and extracellular fibronectin filaments associated with subplasmalemmal plaque material. The fibronexus represents an intercellular junction between myofibroblasts, but in particular is a device for providing contact between myofibroblasts and matrix that mediates continuity between intracellular contractile filaments and extracellular matrix proteins. Immunoelectron microscopy in particular has shown that the intracellular filaments contain actin. The extracellular filaments contain fibronectin and collectively form the fibronectin fibril. The plaque probably contains such proteins as vinculin, talin, alpha-actinin, and integrin. Under appropriate biologic development and fixation conditions, the fibronectin fibril of the fibronexus is characterized by and distinguished from lamina by enhanced density, a rigid appearance, failure to adhere closely to the contours of the cell surface (except focally near the plaque material), and a longitudinally filamentous substructure. Confirmation of the presence of a fibronectin fibril may be obtained by the finding of intense cell surface staining with an antifibronectin antibody. Problems in identifying the fibronexus may be encountered, however, due to poor development and fixation, in which case the filamentous substructure may be inapparent. The fibronexus is such a typical feature of and is often so conspicuous in myofibroblasts that it can be regarded as perhaps essential for the interpretation of myofibroblastic differentiation. Structures with a similar appearance have been documented in fundamentally nonmyofibroblastic cells; these include aortic and scleral spur smooth muscle cells and endothelium. Uncertainties remain in the protein composition of the fibronexus, the nature of its contact with the matrix, and its relationship to similar structures seen in nonmyofibroblastic cells. Immunoelectron microscopy provides a potential means of clarifying some of these questions.
    • Brigatinib (BRG) vs crizotinib (CRZ) in ALK TKI-naive ALK plus NSCLC: Final results from ALTA-1L

      Popat, S.; Kim, H. R.; Ahn, M. J.; Yang, J. C.; Han, J. Y.; Hochmair, M. J.; Lee, K. H.; Delmonte, A.; Campelo, M. R. G.; Kim, D. W.; et al. (2021)
      Background In 2 planned interim analyses of ALTA-1L (NCT02737501), BRG BIRC-assessed PFS was superior to CRZ. We report final ALTA-1L results. Methods Patients (pts) with ALK TKI�naive advanced ALK+ NSCLC were enrolled and stratified by baseline (BL) brain metastases (BM) and prior chemotherapy (CT). One prior CT for advanced NSCLC and asymptomatic BM was allowed. Pts were randomized 1:1 to BRG 180 mg qd (7-day lead-in at 90 mg) or CRZ 250 mg BID. Pts in the CRZ arm were offered BRG at progression. Primary endpoint: BIRC-assessed PFS (RECIST v1.1). Secondary endpoints included confirmed iORR, iPFS by BIRC, OS, safety, and QoL. Results 275 pts randomized (BRG/CRZ, n=137/138); median age 58/60 y; prior CT 26%/27%; BL BM 29%/30%. As of 29 Jan 2021 (last patient contact), median follow-up was (BRG/CRZ): 40.4/15.2 mo, with 166 (73/93) PFS events. BIRC-assessed PFS HR was 0.48 (95% CI: 0.35�0.66, log-rank P<0.0001); BRG mPFS was 24.0 mo (95% CI: 18.4�43.2) vs CRZ 11.1 mo (95% CI: 9.1�13.0); 3-yr PFS rate was (BRG/CRZ) 43%/19%. Investigator-assessed PFS HR was 0.43 (95% CI: 0.31�0.58, mPFS 30.8 vs 9.2 mo). mDoR (BIRC) was 33/14 mo. Median OS was not reached in either group (events BRG/CRZ: 41/51; HR: 0.81 [95% CI: 0.53�1.22]; log rank P=0.3311); 3-yr OS was 71%/68%. In pts with BL BM, OS HR was 0.43 (95% CI: 0.21�0.89; Table); in pts with no BL BM, 1.16 (0.69�1.93). Most common grade ?3 TEAEs: BRG: increased CPK (26%) and lipase (15%), hypertension (14%); CRZ: increased ALT (10%), lipase, (8%), AST (7%). Any grade ILD/pneumonitis (BRG/CRZ): 4.4%/2.2%; discontinuation due to AE: 13.2%/8.8%. Median time to worsening in pt-reported global health status/QoL was (BRG/CRZ) 26.7/8.3 mo; HR: 0.69 (95% CI: 0.49�0.98). Conclusions BRG demonstrated durable overall and intracranial efficacy, and the tolerability profile remained consistent and manageable despite extended treatment duration, confirming BRG as an effective standard-of-care treatment in pts with treatment-naive ALK+ NSCLC.
    • Brigatinib (BRG) vs crizotinib (CRZ) in Asian vs non-Asian patients (pts): Update from ALTA-1L

      Ahn, M. J.; Kim, H. R.; Yang, J. C. H.; Han, J. Y.; Li, J. Y. C.; Hochmair, M. J.; Chang, G. C.; Delmonte, A.; Lee, K. H.; Campelo, M. R. G.; et al. (2020)
      Background: We report updated data with BRG vs CRZ in Asian vs non-Asian pts with ALK TKIenaive advanced ALK+ NSCLC from ALTA-1L (NCT02737501) second interim analysis (IA2). Methods: Pts were stratified by baseline (BL) CNS metastases and prior chemotherapy (CT). All pts had brain MRI at each tumor assessment. Pts were randomized 1:1 to BRG 180 mg qd (7-day lead-in at 90 mg) or CRZ 250 mg bid. Primary endpoint: blinded independent review committee (BIRC)eassessed PFS (RECIST v1.1). Secondary endpoints by BIRC included confirmed ORR, median duration of response (mDoR) in confirmed responders, and intracranial PFS (iPFS). Results: 275 pts were randomized; 108 Asian (BRG/CRZ, n¼59/49), 167 non-Asian (n¼78/89); median age: Asian 55/56 y; non-Asian 60/60 y. 32/24% of Asian pts vs 22/ 28% of non-Asian pts received prior CT; 36/33% vs 24/28% had BL CNS metastases. As of IA2 data cutoff (28 Jun 2019), there were (BRG vs CRZ) 26 vs 31 BIRC-assessed PFS events in Asian pts and 37 vs 56 in non-Asian pts. In Asian pts, median BIRC-assessed PFS (mPFS) was 24.0 mo (95% CI 18.4enot reached [NR]) with BRG vs 11.1 mo (9.2e 15.6) with CRZ (HR 0.38 [95% CI 0.22e0.65]; log-rank P¼0.0006). The PFS result is also in favor of BRG in non-Asian pts. Confirmed ORR (95% CI) in Asian pts was (BRG/CRZ) 78% (65e88)/71% (57e83), P¼0.3397; in non-Asian pts 71% (59e80)/56% (45e67), P¼0.0556. Duration of confirmed response and iPFS were both longer for BRG in both Asian and non-Asian pts. Safety profile was similar in Asian vs non-Asian pts. Conclusions: BRG showed sustained improvement in systemic and intracranial PFS vs CRZ in Asian and non-Asian pts with ALK inhibitorenaive ALK+ NSCLC, with numerically better BIRC-assessed PFS HRs in Asian pts.
    • Brigatinib (BRG) vs crizotinib (CRZ) in patients (Pts) with ALK inhibitor-naive advanced ALK plus NSCLC from ALTA-1L

      Yang, JCH; Kim, HR; Ahn, MJ; Han, JY; Hochmair, MJ; Lee, KH; Delmonte, A; Campelo, MRG; Kim, DW; Felip, E; et al. (2019)
    • Brigatinib (BRG) vs crizotinib (CRZ) in the phase III ALTA-1L trial

      Califano, Raffaele; Hochmair, MJ; Gridelli, C; Delmonte, A; Garcia, Campelo, MR; Bearz, A; Griesinger, F; Morabito, A; Felip, E; Ghosh, S; et al. (2019)
    • Brigatinib (BRG) vs crizotinib (CRZ) in the phase III ALTA-1L trial

      Califano, Raffaele; Hochmair, MJ; Gridelli, C; Delmonte, A; Campelo, MRG; Bearz, A; Griesinger, F; Morabito, A; Felip, E; Ghosh, S; et al. (2019)
    • Brigatinib experience on the ALK project

      Gomes, Fabio; Tokaca, N; Yip, K; Ghosh, S; Newsom-Davis, T; Greystoke, A; Mills, H; Ahmed, S; Harle, AS; Ayre, G; et al. (2019)
    • Brigatinib experience on the ALK project

      Gomes, Fabio; Tokaca, N; Yip, K; Ghosh, S; Newsom-Davis, T; Greystoke, A; Mills, H; Ahmed, S; Harle, AS; Ayre, G; et al. (2019)
    • Brigatinib use in England - where next?

      Gomes, Fabio; Yip, K; Blackhall, Fiona H; Greystoke, A; Califano, Raffaele; Ghosh, S; Newsom-Davis, T; Mills, H; Ahmed, S; Harle, A; et al. (2018)